teenCOVE (P203) (Adolescents 12-17Y), 2021 NCT04649151
Spikevax (Moderna mRNA-1273 COVID-19 vaccine) (n=2489) vs. placebo (n=1243)
randomized controlled trial
some concerns about risk of bias
Two vaccinations of mRNA-1273 given 28 days apart
Each injection containing 100 μg, for a total dose of 200 μg, 28 days apart.
Placebo
Two doses 28 days apart.
COVID-19 prophylaxis (children)
Double-blind.
26 sites in the United States.
Phase 2-3.
kidCOVE (part 2), 2022 NCT04796896
Spikevax (Moderna mRNA-1273 COVID-19 vaccine) (n=3005) vs. placebo (n=997)
randomized controlled trial
risk of bias NA
two dose s of mRNA-1273 given 28 days apart
selected dose during part 1
placebo
COVID-19 prophylaxis (children)
double blind
US, Canada